Chief Business Officer · BIOCRYST PHARMACEUTICALS INC (BCRX)

Megan Sniecinski

A named executive officer of BIOCRYST PHARMACEUTICALS in every fiscal year CompBrief holds from FY2019 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$2,012,335

Salary $456,750Stock awards $0

FY2019: $2,176,954

5th of 6 named executive officers at Biocryst Pharmaceuticals by FY2020 total.

6 named officers on file for BIOCRYST PHARMACEUTICALS, FY2020

Megan Sniecinski’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing
  • BCRX’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how BIOCRYST PHARMACEUTICALS’s whole pay program stands against its peers

  • BIOCRYST PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on BCRX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 13, 2021 (DEF 14A).

Free

Get Megan Sniecinski’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Megan Sniecinski compensation by year

BIOCRYST PHARMACEUTICALS Summary Compensation Table · all 2 fiscal years held
In US dollars, as BIOCRYST PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020
Salary$225,000$456,750
Bonus$0$0
Stock awards$0$0
Option awards$1,773,364$1,271,385
Non-equity incentive$153,000$228,375
Pension and deferred compensation$0$0
All other$25,590$55,825
Total$2,176,954$2,012,335

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIOCRYST PHARMACEUTICALS INC DEF 14A filed April 13, 2021, accession 0001171843-21-002454, and prior-year filings. Open the filing on EDGAR.

How this page was built: the BIOCRYST PHARMACEUTICALS INC filed document, accession 0001171843-21-002454. Every figure is read from that document and cited to the page and table it appears in. Filed April 13, 2021.

$2.2M
$2.0M
FY19
FY20
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
Option350,000—$3.71
Option180,000—$3.23
Option225,000—$8.31

Per the Outstanding Equity Awards at Fiscal Year-End table in BIOCRYST PHARMACEUTICALS INC's FY2020 proxy; value at the fiscal year-end close, as the company printed it.

BIOCRYST PHARMACEUTICALS’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Jon StonehousePresident, Chief Executive Officer and Director$6,034,941
Anthony DoyleChief Financial Officer$4,117,930
MBBS William P. SheridanChief Medical Officer$2,679,920
Yarlagadda BabuChief Discovery Officer$2,264,785
Megan Sniecinski · this pageChief Business Officer$2,012,335
Thomas StaabFormer Senior Vice President and Chief Financial Officer$692,790

The full BIOCRYST PHARMACEUTICALS compensation record

free company brief

This page is one person within BIOCRYST PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the BIOCRYST PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BIOCRYST PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Megan Sniecinski's compensation dossier · One-time report. No refunds.